Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tyra Biosciences, Inc.NASDAQ: TYRA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $7.85M rose 22.2% year over year, ahead of the +17.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.2% holds above the trailing-twelve-month pace of +17.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.01M USD
- Year-over-year change
- +22.8%
- 4-year CAGR
- +76.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.01M | +22.8% |
| FY2024 | 2024-12-31 | 22.8M | +68.6% |
| FY2023 | 2023-12-31 | 13.53M | +27.7% |
| FY2022 | 2022-12-31 | 10.59M | +266.7% |
| FY2021 | 2021-12-31 | 2.89M | — |
Stock-Based Compensation vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 stock-based compensation of $29.43M is the 4th largest of the 11 companies compared; the peer median is $16.57M.
- Its year-over-year change of +17.2% is the 6th highest of 11, against a peer median of +19.9%.
- Over three fiscal years its annual growth of +38.3% compares with a peer median of +23.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.79M | +1.8% | +32.7% | 179.5% | |
| LTM Mar 2026 | $37.68M | +13.4% | +12.1% | 52.6% | |
| LTM Mar 2026 | $34.28M | -12.0% | +8.8% | — | |
| LTM Mar 2026 | $29.43M | +17.2% | +38.3% | — | |
| LTM Mar 2026 | $25.38M | +66.4% | — | — | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $17.41M | +79.5% | +164.6% | — |
| LTM Mar 2026 | $15.73M | +224.1% | +209.1% | — | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| Peer median (excluding TYRA) | $16.57M | +19.9% | +23.0% | 22.8% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.89M | 10.59M | 13.53M | 22.8M | 28.01M |
| Change in Working Capital | (481K) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.49M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.97M) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Other Non-Cash Items | 3K | 3K | (1.25M) | (5.88M) | (2.12M) |
| Operating Cash Flow | (23.75M) | (50.29M) | (50.14M) | (69.77M) | (95.14M) |
| Capital Expenditures | (661K) | (559K) | (770K) | (664K) | (141K) |
| Acquisitions (Net) | 16K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (143.84M) | (263.62M) | (101.25M) |
| Sales of Investments | 0 | 0 | 0 | 165.89M | 173.86M |
| Other Investing Activities | 16 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (645K) | (559K) | (144.61M) | (98.4M) | 72.46M |
| Debt Repayment | (9K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 181.22M | 632K | 1.54M | 200M | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (420K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 514K | 0 | 0 | 2.56M | 0 |
| Financing Cash Flow | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Effect of Forex Changes | 0 | (757K) | 0 | 0 | 0 |
| Net Change in Cash | 286.96M | (50.97M) | (193.21M) | 33.96M | (14.58M) |
| Free Cash Flow | (24.41M) | (50.84M) | (50.91M) | (70.44M) | (95.28M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.